Viri

viri

  1. Tilles G., Wallach D., Taïeb A. 2007. Topical therapy of atopic dermatitis: controversies from Hippocrates to topical immunomodulators. J Am Acad Dermatol, 56(2): 295-302.
  2. Kramer O.N., Strom M.A., Ladizinski B., Lio P.A. 2017. The history of atopic dermatitis. Clin Dermatol, 35(4): 344-348.
  3. Darlenski R., Kazandjieva J., Hristakieva E., Fluhr J.W. 2014. Atopic dermatitis as a systemic disease. Clin Dermatol, 32(3): 409-413.
  4. Rudikoff D., Cohen S.R., Scheinfeld N. 2014. Atopic dermatitis and eczematous disorders. New York, CRC Press, 5-24 str.
  5. Ring J. 2016. Atopic dermatitis-eczema. Švica, Springer International Publishing, 1-13 str.
  6. Thomsen S.F. 2014. Atopic Dermatitis: Natural History, Diagnosis, and Treatment. ISRN Allergy, 2014: 1-7.
  7. Hanifin J.M. 2002. Atopiform dermatitis: do we need another confusing name for atopic dermatitis? Br J Dermatol, 147(3): 430-432.
  8. Weissler A. 2016. Atopic Dermatitis-A New Dawn. Physician Assist Clin, 1(4): 661–682.
  9. Tokura Y. 2010. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci, 58(1): 1–7.
  10. Novak N., Bieber T., Leug D.Y.M. 2003. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol, 112(6): 128-139.
  11. Dharmage S.C., Lowe A.J., Matheson M.C., Burgess J.A., Allen K.J., Abramson M.J. 2014. Atopic dermatitis and the atopic march revisited. Allergy, 69(1): 17–27.
  12. Katayama I., Aihara M., Ohya Y., Saeki H., Shimojo N., Shoji S., Taniguchi M., Yamada H. 2017. Japanese guidelines for atopic dermatitis 2017. Alergol Int, 66(2): 230-247.
  13. Dragoš V. (ur.). AD – atopijski dermatitis: obravnava bolnika v ambulanti osebnega zdravnika. Zbornik predavanj. Združenje slovenskih dermatovenerologov, Ljubljana, 2015.
  14. van der Hulst A.E., Klip H., Brand P.L. 2007. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol, 120(3): 565–569.
  15. Spergel J.M. 2010. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am, 30(3): 269–280.
  16. Wollenberg A., Oranje A., Deleuran M., Simon D., Szalai Z., Svensson A., Barbarot S., vo Kobyletzki L., Taieb A., de Bruin-Weller M., Werfel T., Trzeciak M., Vestergard C., Ring J., Darsow U. 2016. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol, 30(5): 729-747.
  17. Furue M., Chiba T., Tsuji G., Ulzii D., Kido-Nakahara M., Nakahara T., Kadono T. 2017. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int, 66(3): 398-403.
  18. Gittler J.K., Krueger J.G., Guttman-Yassky E. 2013. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol, 131(2): 300-313.
  19. Kantor R., Silverberg J.I. 2017. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol, 13(1): 15-26.
  20. Hartwig I.R., Sly P.D., Schmidt L.A., van Lieshout R.J., Bienenstock J., Holt P.G., Arck P.C. 2014. Prenatal adverse life events increase the risk for atopic diseases in children, which is enhanced in the absence of a maternal atopic predisposition. J Allergy Clin Immunol, 134(1): 160-169.
  21. Bieber T. 2010. Atopic dermatits. Ann Dermatol, 22(2): 125-137.
  22. Koutroulis I., Magnelli L., Gaughan J., Weiner E., Kratimenos P. 2015. Atopic dermatitis is more severe in children over the age two who have increased body mass index. Acta Peadiatr, 104(7): 713-717.
  23. Hanifin J.M., Rajka G. 1980. Diagnostic features of atopic dermatitis. Acta Dermatol Venerol, 60(92): 44–47.
  24. Nicholas M.N., Gooderham M.J. 2017. Atopic Dermatitis, Depression, and Suicidality. J Cutan Med Surg, 21(3): 237-242.
  25. Odhiambo J.A., Williams H.C., Clayton T.O., Robertson C.F., Asher M.I. 2009. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol, 124(6): 1251-1258.
  26. Kim J.P., Chao L.X., Simpson E.L., Silverberg J.I. 2016. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol, 75(4): 681-687
  27. Halvorsen J.A., Lien L., Dalgard F., Bjertness E., Stern R.S. 2014. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. J Invest Dermatol, 134(7): 1847-1854.
  28. Schmitt J., Schwarz K., Baurecht H., Hotze M., Fölster-Holst R., Rodríguez E., Lee Y.A.E., Franke A., Degenhardt F., Lieb W., Gieger C., Kabesch M., Nöthen M.M., Irvine A.D., McLean W.H.I., Deckert S., Stephan V., Schwarz P., Aringer M., Novak N., Weidinger S. 2016. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol, 137(1): 130-136.
  29. Brunner P.M., Silverberg J.I., Guttman-Yassky E., Paller A.S., Kabashima K., Amagai M., Luger T.A., Deleuran M., Werfel T., Eywrich K., Stingl G. 2016. Increasing Comorbidities Suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol, 137(1): 18-25.
  30. Pollak Y., Yirmiya R. 2002. Cytokine-induced changes in mood and behaviour: implications for ‘depression due to a general medical condition’, immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol, 5(4): 389-399.
  31. Yarlagadda A., Alfson E., Clayton A.H. 2009. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont), 6(11): 18-22.
  32. Wei H.T., Lan W.H., Hsu J.W., Huang K.L., Su T.P., Li C.T., Lin W.C., Chen T.J., Bai Y.M., Chen M.H. 2016. Risk of developing major depression and bipolar disorder among adolescents with atopic diseases: A nationwide longitudinal study in Taiwan. J Affect Disord, 203: 221-226.
  33. Cheng C.M., Hsu J.W., Huang K.L., Bai Y.M., Su T.P., Li C.T., Yang A.C., Chang W.H., Chen T.J., Tsai S.J., Chen M.H. 2015. Risk of developing major depressive disorder and anxiety disorders among adolescents and adults with atopic dermatitis: A nationwide longitudinal study. J Affect Disord, 178(1): 60-65.
  34. Werfel T., Heratizadeh A., Aberer W., Ahrens F., Augustin M., Biedermann T., Diepgen T., Fölster-Holst R., Gieler U., Kahle J., Kapp A., Nast A., Nemat K., Ott H., Przybilla B., Roecken M., Schlaeger M., Schmid-Grendelmeier P., Schmitt J., Schwennesen T., Staab D., Worm M. 2016. S2k guideline on diagnosis and treatment of atopic dermatitis – short version. Allergo J Int, 25: 82-95.
  35. Dragoš V. 2006. Atopijski dermatitis-sodobno zdravljenje. Farm vest, 57: 96-99.
  36. Sulzberger M.B., Witten V.H. 1952. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol, 19(2): 101-102.
  37. Burry J.M. 1973. Topical drug addiction: adverse effects of fluorinated corticosteroid creams and ointments. Med J Aust, 1(8): 393-396.
  38. Hajar T., Leshem Y.A., Hanfin J.M., Nedorost S.T., Lio P.A., Paller A.S., Block J., Simpson E.L. 2015. A systemic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol, 72(3): 541-549.
  39. Fukaya M., Sato K., Sato M., Kimata H., Fujisawa S., Dozono H., Yoshiza J., Minaguchi S. 2014. Topical steroid addiction in atopic dermatitis. Drug Healthc Patient Saf, 6: 131-138.
  40. Rapaport M.J., Rapaport V. 2006. The red skin syndromes: corticosteroid addiction and withdrawal. Expert Rev Dermatol, 1(4): 547-561.
  41. Rapaport M.J., Lebwohl M. 2003. Corticosteroid Addiction and Withdrawal in the Atopic: The Red Burning Skin Syndrome. Clin Dermatol, 21(3): 201-214.
  42. Sheary B. 2016. Topical corticosteroid addiction and withdrawal – An overview for GPs. AFP, 45(6): 386-388.
  43. Tilles G., Wallach D., Taïeb A. 2007. Topical therapy of atopic dermatitis: Controversies from Hippocrates to topical immunomodulators. J Am Acad Dematol, 56(2): 295-301.
  44. Leung D.Y., Boguniewicz M., Howell M.D., Nomura I., Hamid Q.A. 2004. New insights into atopic dermatitis. J Clin Invest, 113(5): 651-657.
  45. Sidbury R., Khorsand K. 2017. Evolving Concepts in Atopic Dermatitis. Curr Allergy Asthma Rep, 17(7): 42.
  46. Avčin T. Atopijski dermatitis: patogeneza, klinična slika in diagnostika. Pediatrična alergologija. Ljubljana: Klinični center, Pediatrična klinika, Služba za alergologijo in revmatske bolezni, 2002: 69–75.
  47. Hren M., Retelj S. 2010. Atopijski dermatitis-problemi in pomen pravilne nege kože. Slov Pediatr, 17: 82-86.
  48. Mier P.D. 1975. Earliest description of the atopic syndrome? British J Dermatol, 92(3): 359.
  49. Gittler J.K., Wang J.F., Orlow S.J. 2017. Bathing and Associated Treatments in Atopic Dermatitis. Am J Clin Dermatol, 18(1): 45-57.
  50. Yamanaka K., Motomura E., Noro Y., Umeda K., Morikawa T., Umeda-Togami K., Omoto Y., Isoda K., Kondo M., Tsuda K., Okuda M., Gabazza E.C., Mizutani H. 2015. Olopatadine, a non-sedating H1 antihistamine, decreases the nocturnal scratching without affecting sleep quality in atopic dermatitis. Exp Dermatol, 24(3): 227–229.
  51. Lübbe J. 2003. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol, 4(9): 641-654.
  52. Schmitt J., Schäkel K., Schmitt N., Meurer M. 2007. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol, 87(2): 100-111.
  53. Institute for Clinical and Economic Review. Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value. Final Evidence Report and Meeting Summary, maj 2017.
    https://icer-review.org/topic/atopic-dermatitis/ (stran obiskana dne 12. 11. 2017)
  54. Bhat Y.J., Manzoor S., Qayoom S. 2011. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol, 56(1): 30-32.
  55. Besednjak-Kocijančič L. 2004. Pozitivna povezava med atopijskim dermatitisom in debelostjo pri otrocih, mlajših od šestnajst let. Zdrav Vest, 73: 5-7.